INTRODUCTION
============

Sponges are spineless animals belong to phylum, "the pore bearers" (Porifera), serve as most primitive multicelled animals, existing for millions of year ago. Marine sponges are soft bodied, sessile and filter feeders assembling small particles of food from sea water rising through their bodies ([@b56-bt-24-347]; [@b120-bt-24-347]). All over the world, marine sponges are the member of benthic communities of a marine environment, including its biomass as well as its ability to promote pelagic and benthic processes ([@b82-bt-24-347]), also provide habitat for other organisms ([@b64-bt-24-347]). Marine life is a massive source for the synthesis of novel molecules and it need to be studied. According to evolutionary history, marine microorganisms are more diversified than terrestrial microorganisms. Marine sponges frequently produce bioactive compounds as compared to other living microorganisms. Because sponges cannot move and lack physical defenses, they are highly susceptible to marine predators such as fish, turtles, and invertebrates. Thus, it is not surprising that sponges have developed a wide suite of defensive chemicals to deter predators ([@b140-bt-24-347]). They also use their defensive chemicals to keep the offspring of small plants and animals (fouling organisms) from settling onto their outer surfaces ([@b95-bt-24-347]; [@b57-bt-24-347]). These sessile animals are a prolific source of a huge diversity of secondary metabolites that has been discovered over the past 50 years ([@b44-bt-24-347]; [@b15-bt-24-347]; [@b76-bt-24-347]; [@b57-bt-24-347]; [@b116-bt-24-347]). The bioactive compounds are very diverse in both structure and bioactivity. The known species of sponges are more than 8000 (Van soest *et al*., 2014) widely distributed in sea and freshwater environment ([@b61-bt-24-347]).

In the early 1950s, pharmaceutical interest among sponges have been started and it has started by the investigation of the nucleosides spongouridine and spongothymidine in the marine sponge i.e. *Cryptotethya crypta* ([@b10-bt-24-347]; [@b11-bt-24-347]). These nucleosides were the basic root for the synthesis of ara-A, an antiviral drug and ara-C, the first marine-derived anticancer agent ([@b115-bt-24-347]). Currently, ara-C used in the treatment of lymphoma and leukemia, a part of this one of its fluorinated derivative also permitted for the treatment of lung, pancreatic ([@b96-bt-24-347]), breast and bladder cancer ([@b129-bt-24-347]). On the other hand, it also been revealed that lower invertebrates have more lipid components such as sterols, fatty acids and other unsaponifiable elements as compared to vertebrate animals ([@b12-bt-24-347]; [@b110-bt-24-347]). Up till now approximately 20,000 bioactive compounds have been found in marine organisms ([@b62-bt-24-347]). However, most of these biologically active compounds, which are predominantly terpenoids and alkaloids, have been isolated from sponges ([@b77-bt-24-347]). Regarding the diversity of marine compounds, sponges are the most important producer. Every year around 5300 different natural products and new compounds have been isolated from marine sponges ([@b42-bt-24-347]; [@b43-bt-24-347]; [@b44-bt-24-347]). Sponges are most abundantly produce novel compounds, including more than 200 novel metabolites, every year ([@b16-bt-24-347]; [@b142-bt-24-347]). About 300 novel compounds were reported in 2011 from the phylum Porifera ([@b14-bt-24-347]). Moreover, some of the sponge-derived substances are however in a process of a clinical and pre-clinical trial (e.g., as anti-inflammatory or anticancer agents) in comparison of those substances that derived from different marine phylum ([@b15-bt-24-347]: [@b84-bt-24-347]).

Sponge-derived or other marine microorganism's associated bioactive substances have possessed antibacterial, antiviral, antifungal, antimalarial, anthelminthic, immunosuppressive, muscle relaxants and anti-inflammatory activities. Sponge substances have remarkable chemical diversity. A part of uncommon nucleosides, marine sponges also able to produce other classes of amino acid derivatives including cyclic peptides, alkaloids, sterols, terpenes, fatty acids, peroxides, etc. ([Fig. 1](#f1-bt-24-347){ref-type="fig"}) ([@b36-bt-24-347]; [@b15-bt-24-347], [@b16-bt-24-347]; [@b132-bt-24-347]; [@b111-bt-24-347]). Although few representatives from sponges are approved as drugs, hundreds of new compounds with interesting pharmacological activities are discovered from sponges every year. Several sponge-derived compounds are already in clinical trials as agents against cancer, microbial infections, inflammation and other diseases. However, in many cases drug development is severely hampered by the limited supply of the respective compounds, as they are often present only in minute amounts in the sponge tissue. These reasons have moved the pharmaceutical drug discovery programs away from natural products in favor of synthetic approaches. However, the abundance of synthetic compounds with similar chemical functional groups and, therefore, limited chemical diversity has renewed interest in nature as a good resource for finding new fascinating leads to be applied to design the next generation of drugs.

In most cases development and production of sponge-derived drugs is hindered by environmental concerns and technical problems associated with harvesting large amounts of sponges. The presence of possibly producing microbial symbionts is therefore especially intriguing, as a sustainable source of sponge-derived drug candidates could be generated by establishing a symbiont culture or by transferring its biosynthetic genes into culturable bacteria. For example, Manzamine alkaloids, the promising leads for extended preclinical assessment against malaria, tuberculosis and HIV, have been previously isolated from sponge *Acanthostrongylophora* sp. and have also been isolated from the associated microorganism *Micromonospora* sp. ([@b59-bt-24-347]). A dinoflagellate *Prorocentrum lima* produces okadaic acid ([@b97-bt-24-347]), first isolated from the host sponge *Halichondria okadai* ([@b72-bt-24-347]). A *Vibrio* sp. produces peptide, andrimid and brominated biphenyl ethers ([@b83-bt-24-347]) that was purified from the *sponge Hyatella* sp. extract ([@b103-bt-24-347]) and sponge *Dysidea sp*. ([@b41-bt-24-347]).Thus, the microbial association that occurs on or in sponges could be of great interest as a solution of the supply problem of most of pharmaceutical compounds produced by sponges.

Therefore, the main focus of this review is to highlight the survey of discoveries of products derived from marine sponges which displayed *in vivo* potency or effective *in vitro* activity against infectious and parasitic diseases, including protozoal, bacterial, fungal and viral infections and their mode of action by which they interpose with the pathogenesis of human diseases. The knowledge of mechanisms of actions is very necessary for the development of the drug from a bioactive compound. For example, many secondary metabolites inhibit the growth of cancer cell lines or show the highest degree of antibiosis activity, but they do not prove that they are fit as anti-cancer or anti-microbial agents because they may exhibit severe adverse effects. Our objective was to highlight the compounds by disease type, their mode of action and the greatest potential to drive towards clinically useful treatments.

ANTIBACTERIAL ACTIVITY
======================

At the beginning of the twenty century, the first antibiotics detection left the scientific and social society untrained, when the antibiotic-resistant bacteria emerged. This antibiotic-resistance bacterium has multiplied very swiftly and creates a considerable problem while both *Staphylococcus aureus* and some pathogenic bacteria are involved in causing the infections. According to Davies and Davies ([@b122-bt-24-347]), lately vancomycin became ineffective to cure the infections caused by methicillin-resistant *S. aureus* (MRSA). The importance of drug-resistant bacterial infection has produced an imperative requirement for the quick and sustained development of new antibiotics classes, which may keep pace with the varying face of bacterial antibiotic vulnerability. Therefore, the first precedence of a biochemical research community is the innovation and improvement of new antibiotics.

The marine sponges crude extracts exhibited a low level of anti-bacterial activity against marine bacteria while a high level of antibacterial activity was exhibited against terrestrial bacteria ([@b2-bt-24-347]; [@b1-bt-24-347]; [@b91-bt-24-347]; [@b144-bt-24-347]; [@b153-bt-24-347]). The antimicrobial screenings of crude extracts from 101 Arctic sponges against bacteria associated with opportunistic infections showed that about 10% of the sponges yielded significant antimicrobial activities, with IC50 values from 0.2 to 5 μg/mL ([@b142-bt-24-347]). In every year, some new molecules containing antibiotic properties are introduced, but in marine sponges, their ubiquity is on the top.

After an early screening test by Burkholder and Xue ([@b21-bt-24-347]; [@b153-bt-24-347]), it was noted that 18 sponges out of 31 exhibited antibacterial effect while some of them were very strong against Gram-positive and Gram-negative bacteria. It was observed that marine sponges screening test for an antibacterial activity directed to both the isolation and characterization of a wide range of active substances, containing some promising therapeutic ([@b88-bt-24-347]; [@b98-bt-24-347]; [@b87-bt-24-347]). Marine sponges produced up to 800 antibiotic substances ([@b141-bt-24-347]), while some other antibacterial agents have also been identified from sponges by marine natural products community. However, no antibacterial product was reported yet in the discovered marine natural product but many of them are under investigation in current research. More or less isolated marine sponges substances with antibacterial activity are shown in ([Table 1](#t1-bt-24-347){ref-type="table"}). Manoalide, one of the first sesterterpenoids to be isolated from a marine sponge *Luffariella variabilis*, was found to be an antibiotic ([Fig. 1](#f1-bt-24-347){ref-type="fig"}) ([@b35-bt-24-347]). This is the only example of antibiotic sesterterpenoid discovered so far.

ANTIVIRAL ACTIVITY
==================

The officially approved antiviral drug armamentarium for clinical use contains approximately 40 substances and most of them were discovered recently. It was reported that half of the recently discovered substances are used for the human immunodeficiency virus (HIV) infection treatment ([@b33-bt-24-347]; [@b154-bt-24-347]). The significance of new antiviral agents development help to increase the number of available drugs becomes clear. It was observed that the adenovirus serotype 5 (AdV-5) is much constant in the environment for long time, and connected to respiratory infections with no special cure ([@b152-bt-24-347]; [@b132-bt-24-347]). There are some viruses such as rotaviruses, which are mainly responsible for sever gastroenteritis in human and animals. The treatment of diarrhea is only possible by symptomatic, which may cause the infection of children and immune compromised patients even it can lead to death ([@b150-bt-24-347]; [@b55-bt-24-347]).

Some new approaches being use to introduce new antiviral agents from marine sources and many promising therapeutic leads because sponges are one of the rich source of antiviral property compounds ([Table 2](#t2-bt-24-347){ref-type="table"}). Maximum quantities of HIV-inhibiting compounds were introduced, while they do not reflect greater potential of sponges to fight against AIDS compared with other viral diseases. Researchers use screening techniques for anti-HIV activity has led to introducing of different compounds, although the system of inhibition is still not clear. It has been reported recently by many researchers that HIV-inhibiting compounds were produced by different sponges ([@b46-bt-24-347]; [@b118-bt-24-347]; [@b154-bt-24-347]; [@b125-bt-24-347]). For instance, avarol is a compound which inhibits the progression of HIV infection up to some extent. The data form *in vitro* experiment and animal show that avarol combines have very useful properties and increase humoral immune response ([@b99-bt-24-347]; [@b3-bt-24-347]). HIV inhibits completely by avarol and blocking the production of natural UAG suppressor glutamine transfer tRNA. After viral infection, the production of tRNA is up-regulated, which is necessary for the viral protease and viral proliferation synthesis. The low Concentration of avarol 0.3 and 0.9 μM resulted in 50 and 80% of inhibition of virus released from infected cells ([@b99-bt-24-347]). Moreover, the derivatives of avarol such as 6′-hydroxy avarol and 3′-hydroxy avarone were noted as very strong inhibitors of HIV reverse transcriptase ([Fig. 2](#f2-bt-24-347){ref-type="fig"}). Avarol play very important role during the early stages of HIV infection and it also has a specific target for antiviral drugs, while it convert the viral genomic RNA into pro-viral double-stranded DNA, and later on it integrated into the host chromosomal DNA ([@b80-bt-24-347]).

Another important antiviral discovery from marine source reported is the nucleoside ara A (vidarabine) which was isolated from *Cryptotethya crypta* sponge and was first synthesized in 1960 ([@b148-bt-24-347]). Ara-A is an arabinosyl nucleosides which inhibits viral DNA synthesis ([@b12-bt-24-347]; [@b16-bt-24-347]; [@b125-bt-24-347]). Research proved that our biological systems can recognize nucleoside base just after sugar moiety modifications, then chemists started to replace the pentoses by acyclic entities or with sugar molecules, it lead to the development of azidothymidine (zidovudine) drug. An examples of semisynthetic arabinosyl nucleosides modification are Ara-A, acyclovir, ara-C ([Fig. 1](#f1-bt-24-347){ref-type="fig"}, [3](#f3-bt-24-347){ref-type="fig"}) and azidothymidine are in clinical use ([@b32-bt-24-347]; [@b125-bt-24-347]).

ANTIFUNGAL ACTIVITY
===================

In the last decades, the fungal infection (especially invasive mycoses) dramatically increased in those individuals suffering from AIDS, immune depressants, hematological malignancies, and transplant recipients, increased the need of new antifungals ([@b49-bt-24-347]; [@b114-bt-24-347]). Fungal infection remains a major direct cause of death for those patients who are treated for malignant disease ([@b127-bt-24-347]; Ellis *et al*., 2000). Fungal causing malignant diseases are a major cause of life threatening diseases as well as resistance to them is a major problem ([@b49-bt-24-347]; [@b51-bt-24-347]; [@b147-bt-24-347]; [@b52-bt-24-347]). Immunocompromised patients are mainly infected by *Candida*, *Aspergillus*, *Cryptococcus* and other opportunistic fungi. Currently using fungicides are less diversified than antimicrobial substances and their use is restricted because of biological system toxicity ([@b119-bt-24-347]).

Jaspamide is the first example of cyclodepsipeptide 19-membered macrocyclic depsipeptide ([Fig. 1](#f1-bt-24-347){ref-type="fig"}) isolated from the sponges *Jaspis sp* has a selective *in vitro* antifungal activity with MIC of 25 μg/ml against *C. albicans* while *in vivo* topical activity of a 2% solution against *Candida* vaginal infection in mice ([@b156-bt-24-347]; [@b38-bt-24-347]). The other examples of important antifungals examined *in vitro* with MIC values have been listed ([Table 3](#t3-bt-24-347){ref-type="table"}).

ANTIMALARIAL PROPERTIRES
========================

In sub- Saharan Africa, malaria is a predominant disease including that it is also serious public health problem in some areas of South America and Southeast Asia. Most of the malaria related deaths are caused by *Plasmodium falciparum* parasite ([@b92-bt-24-347]; [@b24-bt-24-347]; [@b151-bt-24-347]). Recently, most widely disseminated malarial species all over the world is *Plasmodium vivax*. *P. vivax* is the predominant specie in the Asia and America, while in Brazil this species represents around 80% of clinical issue annually ([@b20-bt-24-347]). Sub-Saharan Africa carries a disproportionately high share of the global malaria burden. In 2015, the region was home to 88% of malaria cases and 90% of malaria deaths ([@b8-bt-24-347]; [@b151-bt-24-347]). During last decades, some of the antimicrobial compounds have been derived from sponges ([Table 4](#t4-bt-24-347){ref-type="table"}, [Fig. 4](#f4-bt-24-347){ref-type="fig"}). Increasing resistance among Plasmodium strains created a need to discover new antimalarial compounds. *Plasmodium falciparum* has become resistant toward chloroquinone, pyrimethamine, and sulfadoxine (Bwijo *et al*., 2003). *In vitro*, selective antimalarial activity against *Plasmodium falciparum* has been recorded by different isonitrilese, isothiocyanates and terpenoid isocyanates from *Cymbastela hooperi* ([@b73-bt-24-347]). Including that a number of free carboxylic acids (*Diacarnus levii*) after esterification were used as precursors to synthesize some new cyclic norditerpene peroxides. These epidioxy-substituted norsesterterpenes and norditerpenes endoperoxides from marine sponge *Diacarnus megaspinorhabdosa* showed antimalarial activity against both chloroquine-resistant *P. falciparum* and chloroquine-sensitive ([@b30-bt-24-347]; Yang *et al*., 2014).

The most capable and promising antimalarial compound, manzamines have been isolated from a number of sponges ([@b126-bt-24-347]; [@b155-bt-24-347]; Fattorusso and Taglialatela, 2009). Manzamine A displayed a potent *in vitro* activity against *P. falciparum* (D6clone), with MIC of 0.0045 μg/ml ([@b126-bt-24-347]; [@b6-bt-24-347]). According to research antimalarial activity of manzamine A is due to enhancing immune response ([@b4-bt-24-347]).

ANTI-INFLAMMATORY ACTIVITY
==========================

Body inflammation is caused by physical or chemical damage or due to infection. In this case, blood is oozing out from blood vessels into tissues ([@b137-bt-24-347]; Franceschi and Campisi, 2014). Manolide is the first sesterterpenoids anti-inflammatory drug derived from marine sponges with several other pharmaceutical properties (Mayer and Jacobs, 1998). Its Anti-inflammatory action is basically an irreversible inhibition of the release of arachidonic acid from phospholipid membrane by the mechanism of preventing the phospholipase A2 enzyme from the binding to the membrane of phospholipid, the reason is that it increases the concentration of intracellular arachidonic acid that results in the upregulation of the inflammation mediators synthesis as a leukotrienes and prostaglandins. The Mode of action of sponge-derived anti-inflammatory substances has different from other non-steroidal anti-inflammatory drugs (NSAIDS). Only a few of sponge-derived substances have the capability to inhibit lipoxygenase, another enzyme which is involved in the inflammatory response ([@b25-bt-24-347]) ([Fig. 5](#f5-bt-24-347){ref-type="fig"}).

ANTITUMOR ACTIVITY
==================

In the tumor development protein kinase C (PKC) is an essential factor ([@b19-bt-24-347]; [@b70-bt-24-347]). Many of the sponge-derived substances are PKC inhibitors. Worldwide, PKC inhibitors have attracted interest because of providing evidence, that extreme levels of PKC enzymes are involved in the pathogenesis of psoriasis, arthritis and especially in the development of tumor ([@b19-bt-24-347]; [@b70-bt-24-347]). PKC serve as a receptor for tumor-promoting phorbol esters by the binding prevention of carcinosarcoma cells with Endothelium ([@b79-bt-24-347]; [@b70-bt-24-347]).

Fucosyltransferase inhibitors, like octa and nonaprenylhydroquinone sulfates, which were derived from *Sarcotragus sp*. ([@b146-bt-24-347]), may be capable candidates for regulating inflammatory processes like arthritis or for opposing tumor growth.

There are many other sponge derived compounds having anti-tumor potency with different kind of mechanisms of actions ([Table 5](#t5-bt-24-347){ref-type="table"}). These are divided into three types.

Non-specific inhibitors
-----------------------

Nonspecific anti-tumor inhibitors are important compounds to treat cancer but in unusual conditions because these compounds also have toxic effects on healthy cells of a body. Example is adociasulfates (titerpenoid hydroquinones), isolated from *Haticlona sp*. Etc ([@b13-bt-24-347]; [@b157-bt-24-347]) and they are protein inhibitors by binding to microtubule binding site "locking up" protein motor function and there by blocking cell division.

Specific inhibitors
-------------------

Specific inhibitors are specifically active against the tumor. For example, agosterol A derived from marine spongia can reverse the over appearance of membrane glycoproteins. These proteins are responsible for multidrug resistance in human carcinoma cells. Another example belongs to these inhibitors group is salicylihamide A. The first natural isolated from *cinachyrella spp*. is 6- hydroximino-4-en-3 ([@b54-bt-24-347]).

Inhibitors of a cancer cell of certain types
--------------------------------------------

Growth inhibitory active compounds against tumor cell line have been isolated but its mechanism of action is still unknown. For example Discorhabdin D ([@b107-bt-24-347]) etc.

IMMUNE SUPPRESSIVE ACTIVITY
===========================

Nitric oxide synthetase inhibitors, as anti-cancer agents are also responsible for the immune system suppression by downregulating the T-cells ([@b54-bt-24-347]). The ratio of Immune system suppression is very highly desired in case of hypersensitivity to antigens (e.g. allergies) medicines or organ transplantations. The cases in which patients receive any donor organ have to persist on life-long medication to prevent rejection by the body immune system as a foreign agent, and for that reasons, it is very important that these medicines should be specific suppressors. To prevent this autoimmune body defensive response and rejection of the donor organ, therefore, now it is a very crucial need for new specific immunosuppressors. A number of new biomolecules with strong immunosuppressive activities, which interfere at different sites of the immune response system have been discovered in marine sponges.

*Dysidea sp* have a large contribution in the portion of biomolecules ([@b90-bt-24-347]; [@b88-bt-24-347]; [@b87-bt-24-347]). 3 polyoxygenated sterols derived from *Dysidea sp*. in North Australia having a strong selective immunosuppressive capability of blocking the binding of interleukin 8 (IL-8), a cytokine that attracts neutrophil into tissue injury site, to the IL-8 receptor ([@b31-bt-24-347]). Thus, these polyoxygenated sterols have a specific selective inhibition on primary immune response ([Fig. 6](#f6-bt-24-347){ref-type="fig"}). Correspondingly, Pateamine A derived from *Mycale sp*., are the selective inhibitors of the production of interleukin 2 (IL-2), IL-2 helps in activation of B cells and T resting cells leading to cause antigen-antibody reaction and produce Secondary immune response.([@b123-bt-24-347]; [@b106-bt-24-347]). Some examples for these suppressants are mentioned in [Table 6](#t6-bt-24-347){ref-type="table"}, [Fig. 6](#f6-bt-24-347){ref-type="fig"}.

CARDIOVASCULAR AGENTS
=====================

Some of the very common blood-related diseases like diabetes, thrombosis, atherosclerosis etc. have been treated by some marine sponge's derived substances ([Table 7](#t7-bt-24-347){ref-type="table"}, [Fig. 7](#f7-bt-24-347){ref-type="fig"}). The mechanism of blood coagulation is managed by a complex photolytic cascade that leads to the production of fibrin. Fibrin, a major component responsible for blood coagulation has been generated by the peptide cleaving of fibrinogen by thrombin ([@b75-bt-24-347]). Cyclotheonamide A, isolated from marine sponges Theonella sp ([@b85-bt-24-347]) is an unusual class of Serine protease (an enzyme responsible for the conversion of fibrinogen into fibrin) inhibitor and is a drug of choice for thrombosis ([@b85-bt-24-347]; [@b128-bt-24-347]). Eryloside F derived from *Eryltus formosus sp*. was found to be a potent Thrombin-receptor antagonist ([@b131-bt-24-347]; [@b134-bt-24-347]; [@b69-bt-24-347]). Thrombin receptor plays a central role not only in thrombosis but also the main agent to cause atherosclerosis ([Fig. 7](#f7-bt-24-347){ref-type="fig"}) ([@b26-bt-24-347]; [@b65-bt-24-347]). Atherosclerosis is a disease in which plaque (fats, cholesterol, and calcium etc.) builds up layer by layer inside the arteries and resulting by narrowing of the arteries, causing a barrier to blood circulation leading to serious problems including heart attack, stroke or maybe death ([@b157-bt-24-347]; [@b65-bt-24-347]).

ANTIHELMINTHIC ACTIVITY
=======================

A new macrocyclic polyketide lactam tetramic acid, geodin A Magnesium salt, isolated from the marine sponge *Geodia sp*. exhibited a remarkable nematocidal activity with (LD99=14 μg/ml) against *Haemonchus contortus* ([@b22-bt-24-347]). The mode of action of the pure Geodin A is not explored yet. Two more studies contributed to the search of novel *anthelmintic* marine sponge derived products during 2005--6. Two novel alkaloidal betaines (−)-echinobetaine A (1) and (+)-echinobetaine B (2), isolated from marine sponge Echinodictyum sp proved to be a nematocidal with (LD99=83 and 8.3 μg/ mL, respectively) against commercial livestock parasite *Haemonchus contortus* ([@b23-bt-24-347]). Unfortunately, the mode of action of these compounds was also undetermined. (+)-echinobetaine B's nematocidal potency was comparable to that of "two commercially available synthetic anthelmintic, closantel and levamisole" ([@b23-bt-24-347]).

MUSCLE RELAXANT
===============

Continuous muscles activation caused by disturbances in the neuromuscular communication that result in muscular stress ([@b81-bt-24-347]; [@b39-bt-24-347]; [@b58-bt-24-347]). Muscle relaxants are divided into two parts; centrally and peripherally active. Centrally active can mediate neuromuscular communication while peripherally relaxants are used for local muscle relaxation like stroke or during surgery ([@b47-bt-24-347]; [@b58-bt-24-347]) Xestospongin C ([Fig. 1](#f1-bt-24-347){ref-type="fig"}) isolated from marine sponge *Xestospongia sp* is a potent α-receptor's IP~3~ (Inositol triphosphate) inhibitor and Ca^2+^ (calcium channel) blocker ([@b117-bt-24-347]; [@b48-bt-24-347]; [@b93-bt-24-347]). IP~3~ is a secondary messenger molecule used in signal transduction and it diffuses throughout the cell and increases the Ca^2+^ level and resulting cause's smooth muscles contraction ([Fig. 8](#f8-bt-24-347){ref-type="fig"}) ([@b117-bt-24-347]; [@b101-bt-24-347]). S1319 isolated from a *Dysidea sp*. ([@b135-bt-24-347]) is another substance with a remarkable muscle relaxing capability. Its mechanism of action is to agonist the β-Adrenoreceptor. β-Adrenoreceptors are of two types β-1 and β-2. β-1 receptors are available in heart increases heart rate, myocardial contractility and increases conduction velocity while β-2 receptors are available in lungs and uterus responsible for dilation of bronchial smooth muscles, dilation of blood vessels in skeletal smooth muscles and relaxation of uterus muscles ([@b34-bt-24-347]; [@b9-bt-24-347]). S1319 have the uterus relaxing capability which can be therapeutically used at infant's delivery time ([@b34-bt-24-347]) and bronchodilation property which can be used as antiasthmatic ([@b135-bt-24-347]). However, because of their low selectivity, they have some side effects like activation of β-1 receptors resulting arterial hypertension, tachycardia and coronary heart disease ([@b18-bt-24-347]). Therefore, there is a desired continued research in interest to find selective β-agonists.

CONCLUSION
==========

Sponge-derived substances span a wide range of chemistry (e.g., alkaloid, peptide, terpenoid and polyketides) with an equally variety of biotechnological properties (e.g., Antibacterial, antifungal, antiviral, immunosuppressive, cardiovascular and anti-parasitic) ([@b4-bt-24-347]; [@b141-bt-24-347]). The relationship between the chemistry of the secondary metabolites originated from marine sponges and their mode of action on disease *in vivo* is mostly not obvious (interaction with DNA to combat tumors, or inhibition of α/β receptors to provide muscle relaxation). Moreover, in drug discovery, it is frequently observed that a certain series of compounds that exhibited the most potent inhibitors *in vitro* turned out not to be the drug of choice *in vivo*. It is likely that for every compound prior to coming out to the market, its profile should be with a distinct chemistry, improved bioavailability with lesser side effects.

Now, there are some significant reports of activities from a particular class of metabolites, the manzamines from marine sponges as potential drugs that might be effective against HIV ([@b99-bt-24-347]), malaria ([@b73-bt-24-347]), tuberculosis ([@b129-bt-24-347]) and some other diseases. Other substances with best anti-pathogenic profiles like ara-A, ara-C, acyclovir are in clinical use and are all examples of products originated from marine sponges ([@b99-bt-24-347]).

The potency of sponge-derived medicines lies in the fact that each of these thousands of metabolites and their derivatives has its own specific dose-related efficacy, inhibitory effect, and potential side effects that determine its suitability for medicinal use. Unfortunately, these secondary metabolites are usually present in very trace amounts, and natural stocks are too small which is one of the major obstacles in sustaining the development of widely available medicines. An example is avarol (*D.avara* sponge), a potent anti-HIV drug ([@b99-bt-24-347]), that was in preclinical assessment. However, further studies on this natural product stopped due to an insufficient amount of sponge for its isolation ([@b100-bt-24-347]). In addition, the active core or skeleton of these compounds may be used as a vehicle to generate derivatives with their own distinct efficacy and side effects. Therefore, the most significant challenge in the transformation of bioactive molecules into medicines is now to screen the drug treasure house of sponges and elect those that illustrate a precise mode of action with the desired characteristics towards a disease. A major question for the future still persists, how to actually prepare the potential novel drugs in a bulk quantity.

![The chemical structure of sponge derived molecules. (A) Xestospongin C (Xestospongia sp./macrocyclic bis-oxaquinolizidine. (B) Ara-A (Cryptotethia crypta/unusal nucleoside). (C) Contignasterol (Petrosia contignata/oxygenated sterol). (D) Jaspamide (Hemiastrella minor/macrocyclic lactam/lactone). (E) Manolide (Sesterterpenoids/*Luffariella variabilis* sp). (F) Agelasphin (Agelas mauritianus/agalactosy-ceramide).](bt-24-347f1){#f1-bt-24-347}

![Molecular structures of avarol (a: R1 = H) and 6¢- hydroxy avarol (A: R1 = OH) and avarone (B: R1 = H) and 3¢- hydroxy avarone (B: R1 = OH).](bt-24-347f2){#f2-bt-24-347}

![Molecular structure of Acyclovir and Ara-c (Acyclovir is a drug of choice for Herpes virus).](bt-24-347f3){#f3-bt-24-347}

![Structure of Antimalarial compounds; Manzamine A; Monamphilectine A; Kalihinol A.](bt-24-347f4){#f4-bt-24-347}

![Diagrammatic process of Inflammatory cascade inside the cell. Phospholipase A2 (PLA2) catalyzes the release of membrane-bound arachidonic acid (AA) to free arachidonic acid. Arachidonic acid is then converted to leukotrienes and prostaglandins by lipoxygenase (LOX) and cyclooxygenase-2 (COX-2), respectively. Sponge derived anti-inflammatory substances are mainly inhibitors of PLA2 or LOX, while nonsteroidal anti-inflammatory drugs (NSAID) inhibit COX-2, but also the constitutive COX-1.](bt-24-347f5){#f5-bt-24-347}

![Diagrammatic representation of body immune response towards antigen capturing by Macrophages. The macrophages and T-helper cells secrete many interleukins (IL-x) or macrophage activation factor (MAF), to trigger primary immune response with the help of neutrophils, or the secondary immune response by activating the B and resting T-cells. The activated B cells secrete antibodies which bind to macrophages that already have phagocytized an antigen, and then killed by T-killer cells. The ![](bt-24-347i1.jpg) sign shows the sponge derived substances.](bt-24-347f6){#f6-bt-24-347}

![Blood coagulation (Thrombosis) and atherosclerosis (arterial disease characterized by the deposition of plaques of fatty material on their inner walls) pathway *in vivo* showing central role played by Thrombin. X111 represent *fibrin stabilizing factor* (enzyme responsible for blood coagulation). The ![](bt-24-347i1.jpg) Sign shows the sponge derived compounds.](bt-24-347f7){#f7-bt-24-347}

![The mechanism of adrenergic receptors. A represent α-receptors and trigger the IP~3~ (Inositol triphosphate) which then increase the Ca^2+^ level in cytoplasm and causing muscles contraction. B represents β-adrenoreceptors. The ![](bt-24-347i2.jpg) represents Marine compounds. *Xestospongin C* inhibit the phospholipase enzyme which play a key role in activation of IP~3~ (Inositol triphosphate) and block Ca^2+^ channels. *S1319* B-2 receptor agonist resulting Bronchodilation and uterus relaxation.](bt-24-347f8){#f8-bt-24-347}

###### 

Examples of antibacterial compounds

  Substance                                       Chemistry                          Species                             Activity Spectrum                                MIC Value                                                                                                      References
  ----------------------------------------------- ---------------------------------- ----------------------------------- ------------------------------------------------ -------------------------------------------------------------------------------------------------------------- -------------------
  Discodermins B, C and D                         Cyclic peptide                     *Discodermia kiiensis/Lithistida*   Antibacterial (*B. subtilis*)                    3 μg/ml                                                                                                        [@b86-bt-24-347]
  Arenosclerins A--C                              Alkyl pepridine alkaloid           *Arenosclera brasiliensis*          *S. aureus, P. aeruginosa, M. tuberculosis*      16 μg/ml[^\*^](#tfn1-bt-24-347){ref-type="table-fn"}, 30 μg/ml[^\*\*^](#tfn2-bt-24-347){ref-type="table-fn"}   [@b141-bt-24-347]
  Haliclona cyclamine E                           Alkylpiperidine alkaloids          *Arenosclera brasiliensis*          *S. aureus, P. aeruginosa*                       8 μg/ml[^\*^](#tfn1-bt-24-347){ref-type="table-fn"}                                                            [@b141-bt-24-347]
  CvL                                             Lectine                            *Cliona varians*                    *S. aureus, B. subtilis*                         16 μg/ml[^\*^](#tfn1-bt-24-347){ref-type="table-fn"}                                                           [@b98-bt-24-347]
  Axinellamines B--D                              Imidazo-azolo-imidazole alkaloid   *Axinella sp./Halichondrida*        *H. Pylori, M. Luteus*                           16.7 μg/ml[^\*\*\*^](#tfn3-bt-24-347){ref-type="table-fn"}                                                     [@b143-bt-24-347]
  Caminosides A--D                                Glycolipids                        *Caminus sphaeroconia*              *E. coli, S. aureus*                             16 μg/ml[^\*^](#tfn1-bt-24-347){ref-type="table-fn"}                                                           [@b78-bt-24-347]
  6-hydroxymanzamine E                            Alkaloid                           *Acanthostrongylophora sp.*         *M. tuberculosis*                                0.9 μg/ml[^\*\*^](#tfn2-bt-24-347){ref-type="table-fn"}                                                        [@b121-bt-24-347]
  Cribrostatin 3                                  Alkaloid                           *Cribrochalina sp.*                 *N.gonorrheae* (antibiotic resistant strain)     \-                                                                                                             [@b108-bt-24-347]
  Cribrostatin 6                                  Alkaloid                           *Cribrochalina sp.*                 *S. pneumoniae* (anitibiotic resistant strain)   ≤2                                                                                                             [@b109-bt-24-347]
  Isojaspic acid, cacospongin D and jaspaquinol   Meroditerpenes                     *Cacospongia sp.*                   *S. epidermidis*                                 20 μg/ml                                                                                                       [@b124-bt-24-347]
  Isoaaptamine                                    Alkaloid                           *Aaaptos aaptos*                    *S. aureus*                                      3.7 μg/ml                                                                                                      [@b66-bt-24-347]
  (−)-Microcionin-1                               Terpenoid                          *Fasciospongia sp*                  *M. Luteus*                                      6 μg/ml                                                                                                        [@b50-bt-24-347]

S. aureus

*M. tuberculosis*,

M. luetus

###### 

Examples of antiviral compounds

  Substances               Chemistry                    Species                          Action spectrum                                 References
  ------------------------ ---------------------------- -------------------------------- ----------------------------------------------- -------------------
  4-Methylaaptamine        Alkaloid                     *Aaptos aaptos*                  Anti-viral (HSV-1)                              [@b133-bt-24-347]
  Papuamides A--D          Cyclic depsipeptides         *Theonella* sp.                  Anti-viral (HIV-1)                              [@b46-bt-24-347]
  Ara-A                    Nucleoside                   *Cryptotethya crypta*            HSV-1, HSV-2, VZV                               [@b44-bt-24-347]
  Avarol                   Sesquiterpene hydroquinone   *Dysidea avara*                  HIV-1,UAG suppressor Glutamine tRNA inhibitor   [@b99-bt-24-347]
  Haplosamates A and B     Sulfamated steroid           Xestospongia sp./Haplosclerida   Anti-viral (HIV-1Integrase inhibitor)           [@b118-bt-24-347]
  Dragmacidin F            Alkaloid                     *Halicortex* sp.                 HIV-1                                           [@b29-bt-24-347]
  Hamigeran B              Phenolic Macrolide           *Hamigera tarangaensis*          Anti-viral (herpes and polio virus)             [@b149-bt-24-347]
  Mycalamide A--B          Nucleosides                  *Mycale* sp.                     A59 coronavirus, (HSV-1)                        [@b107-bt-24-347]
  Mirabamides A, C and D   Peptide                      *Siliquariaspongia mirabilis*    Antiviral (HIV-1)                               [@b113-bt-24-347]
  Oroidin                  Alkaloid                     *Stylissa carteri*               Antiviral (HIV-1)                               [@b105-bt-24-347]

###### 

Examples of antiviral compounds

  Substances                    Chemistry                      Species                      Action spectrum                           MIC value                                                                                                        References
  ----------------------------- ------------------------------ ---------------------------- ----------------------------------------- ---------------------------------------------------------------------------------------------------------------- -------------------
  Jaspamide                     Macrocyclic depsipeptide       *Jaspis sp*                  *C.albicans*                              25 μg/ml[^\*^](#tfn5-bt-24-347){ref-type="table-fn"}                                                             [@b156-bt-24-347]
  Eurysterols A--B              Sterols                        *Euryspongia sp*             *C.albicans, Amphoterician B-resistant*   62.5 μg/ml[^\*^](#tfn5-bt-24-347){ref-type="table-fn"}, 15.6 μg/ml                                               [@b17-bt-24-347]
  Naamine D                     Imidazole alkaloid             *Leucetta cf. chagosensis*   *C.neoformans*                            6.25 μg/ml[^\*\*^](#tfn6-bt-24-347){ref-type="table-fn"}                                                         [@b37-bt-24-347]
  Mirabilin B                   Tricyclic guanidine alkaloid   *Monanchora unguifera*       *C.neoformans*                            7.0 μg/ml[^\*\*^](#tfn6-bt-24-347){ref-type="table-fn"}                                                          [@b63-bt-24-347]
  Hamacanthin A                 Indole alkaloid                *Spongosorities sp.*         *C.albicans*                              6.25 μg/ml[^\*^](#tfn5-bt-24-347){ref-type="table-fn"}                                                           [@b104-bt-24-347]
  Macanthins A--B               Indole alkaloid                *Spongosorities sp.*         *C.albicans, C.neoformans*                1.6 μg/ml[^\*^](#tfn5-bt-24-347){ref-type="table-fn"}, 6.2 μg/ml[^\*\*^](#tfn6-bt-24-347){ref-type="table-fn"}   [@b104-bt-24-347]
  Agelasines and agelasimines   Purine derivative              *Agelas sp.*                 *C.krusei*                                15.6 μg/ml                                                                                                       [@b145-bt-24-347]

MIC: Minimum Inhibitory Concentration,

*C. albicans*,

*C. neoformans*.

###### 

Examples of anti-malarial compounds

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Substances                       Chemistry                                     Species                                 Action spectrum                          IC~50~ value                                                 References
  -------------------------------- --------------------------------------------- --------------------------------------- ---------------------------------------- ------------------------------------------------------------ -------------------
  Monamphilectine A                Antimalarial β-lactam                         *Hymeniacidon sp*                       *P. falciparum*                          0.6 μM[^\*\*\*^](#tfn10-bt-24-347){ref-type="table-fn"}      [@b7-bt-24-347]

  Manzamine A                      Alkaloids                                     *e.g., Haliclona sp./ Haplosclerida*\   *T. gondii, P. berghei, P. falciparum*   4.5 ng/ml[^\*\*\*^](#tfn10-bt-24-347){ref-type="table-fn"}   [@b30-bt-24-347]
                                                                                 *Cymbastela hooperi/Halichondrida*\                                                                                                           
                                                                                 *Diacarnus levii/Poecilosclerida*                                                                                                             

  Kalihinol A                      Isonitril-containing kalihinane diterpenoid   *Acanthella sp./Halichondrida*          *P. falciparum*                          0.0005 μg/ml[^\*\*^](#tfn9-bt-24-347){ref-type="table-fn"}   [@b4-bt-24-347]

  Diisocyanoadociane               Tetracyclic diterpene                         *Cymbastela hooperi*                    *P. falciparum*                          0.005 μg/ml[^\*\*^](#tfn9-bt-24-347){ref-type="table-fn"}    [@b94-bt-24-347]

  Halichondramide                  Macrolides                                                                            *P. falciparum*                          0.002 μg/ml[^\*\*^](#tfn9-bt-24-347){ref-type="table-fn"}    [@b73-bt-24-347]

  Sigmosceptrellin-B               Norsesterterpene acid                         *Diacarnus erythraeanus*                *T. gondii, P. falciparum*               1200 ng/ml[^\*^](#tfn8-bt-24-347){ref-type="table-fn"}       [@b73-bt-24-347]

  (E)-Oroidin                      Alkaloids                                     *Agelas oroides*                        *P. falciparum*                          0.30 μg/ml[^\*\*^](#tfn9-bt-24-347){ref-type="table-fn"}     [@b155-bt-24-347]

  Plakortin and dihydroplakortin   Cycloperoxidase                               *Plakortis simplex*                     *P. falciparum*                          1263-1117 nM[^\*^](#tfn8-bt-24-347){ref-type="table-fn"}     [@b138-bt-24-347]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

IC~50~: Inhibitory Concentration,

*P. falciparum* (D10),

*P. falciparum* (D6 clone),

*Chloroquine-resistant P. falciparum* (W2). \[h\] Fattorusso *et al*., 2002.

###### 

Examples of anti-tumor compounds

  Compound                     Chemistry                                                   Species/order                                                                Mode of action                                                        References
  ---------------------------- ----------------------------------------------------------- ---------------------------------------------------------------------------- --------------------------------------------------------------------- -------------------
  Isoaaptamine                 Benzonaphthyridine alkaloid                                 *Aaptos aaptos/Hadromerida*                                                  Protein kinase C inhibitor                                            [@b45-bt-24-347]
  Debromohymenialdisine        Pyrrole-guanidine alkaloid, prenylhydroquinone derivative   *Hymeniacidonaldis/Halichondrida*                                            Protein kinase C inhibitor                                            [@b71-bt-24-347]
  Adociasulfates               Triterpenoid hydroquinones                                  *Sarcotragus sp./ Dictyoceratida Haliclona (aka Adocia) sp./Haplosclerida*   A1, 3-fucosyltransferase inhibitor Kinesin motor protein inhibitors   [@b157-bt-24-347]
  Discodermolide               Linear tetraene lactone                                     *Discodermia dissolute/ Lithistida*                                          Stabilization of microtubules                                         [@b139-bt-24-347]
  Peloruside A                 Macrocyclic lactone                                         *Mycdle hentschett/ Poecilosclerida*                                         Stabilization of microtubules                                         [@b60-bt-24-347]
  Elenic acid                  Alkylphenol                                                 *Plakinastrella sp./ Homosclerophorida*                                      Topoisomerase II inhibitor                                            [@b60-bt-24-347]
  Naamine D                    Imidazole alkaloid                                          *Leucetta cf. chagosensis*                                                   Nitric oxide synthetase inhibitor                                     [@b68-bt-24-347]
  Agelasphin (KRN7000)         a-Galactosylceramide                                        *Agelas mauritianus / Agelasida*                                             NKT cell activator                                                    [@b130-bt-24-347]
  Crambescidins 1--4           Pentacyclic guanidine derivative                            *Crambe crambe/Poecilosclerida*                                              Ca2+/channel blocker                                                  [@b67-bt-24-347]
  Discorhabdin D               Fused pyrrolophenanthroline alkaloid                        *Latrunculia brevis/Poecilosclerida; Prianos sp./Haplosclerida*              Unknown                                                               [@b107-bt-24-347]
  Glaciasterols A and B        9, 11-Secosterol                                            *Aplysilla glacialis/Dendroceratida*                                         Unknown                                                               [@b112-bt-24-347]
  Durumolides A--C             Terpenoid                                                   *Lobophytum duru*                                                            Inducible NOS and COX-2 inhibition                                    [@b27-bt-24-347]
  Plakortide P                 Polyketide                                                  *Plakortis angulospiculatus*                                                 TXB2 inhibition                                                       [@b74-bt-24-347]
  24-methoxypetrosaspongia C   Sesterterpenes                                              *Hyrtios erectus*                                                            Unknown                                                               [@b40-bt-24-347]

###### 

Examples of immunosuppressive compounds

  Compounds                Chemistry            Species/ order                          Mode of action                           References
  ------------------------ -------------------- --------------------------------------- ---------------------------------------- -------------------
  Simplexides              Glycolopids          *Plakortis simplex/*Homosclerophorida   Inhibitors of T cell proliferation       [@b28-bt-24-347]
  Polyoxygenated sterols   Sterol               *Dysidea sp./*Dendroceratida            IL 8 inhibitor                           [@b31-bt-24-347]
  Contignasterol           Oxygenated sterol    *Petrosia contignata/*Haplosclerida     Histamine release inhibitor              [@b136-bt-24-347]
  Pateamine A              Thiazole macrolide   *Mycale sp./Poecilosclerida*            IL-2 inhibitor                           [@b102-bt-24-347]
  Iso-iantheran A          Polyketide           *Ianthella quadrangulata*               Ionotropic P2Y~11~ receptor activation   [@b53-bt-24-347]

###### 

Cardiovascular compound examples

  Compounds           Chemistry                 Species/ order                       Mode of action                                                  References
  ------------------- ------------------------- ------------------------------------ --------------------------------------------------------------- -------------------
  Cyclotheonamide A   Cyclic pentapeptide       *Theonella sp.*/Lithistida           Serine protease inhibitor                                       [@b85-bt-24-347]
  Eryloside F         Penasterol disaccharide   *Eryltus formosus*/Astrophorida      Thrombin receptor antagonist                                    [@b134-bt-24-347]
  Halichlorine        Cyclic aza Polyketide     *Halichondria okadai*/Halichondria   VCAM 1[^\*^](#tfn11-bt-24-347){ref-type="table-fn"} inhibitor   [@b5-bt-24-347]

VCAM: vascular cell adhesion molecule.
